Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Infex Therapeutics

- PMLiVE

International Respiratory Coalition urges policymakers to help lift disease burden

The societal and economic cost of respiratory disease in Europe is reportedly over €600bn

- PMLiVE

Infex doses first patients in Pseudomonas aeruginosa phase 1 study

Pa is a leading cause of non-cystic fibrosis bronchiectasis exacerbations

- PMLiVE

MHRA approves Infex Therapeutics’s study for treatment for non-cystic fibrosis patients

The treatment, for Pseudomonas aeruginosa, will address a chronic and debilitating respiratory condition that has no approved available treatments

- PMLiVE

FDA panel rejects Aradigm/Grifols’ inhaled antibiotic

Further evidence is required to warrant approval according to the US regulator

AstraZeneca AZ

AstraZeneca to explore link between epigenetics and respiratory diseases

Joins forces with Asthma UK, the British Lung Foundation and MRC Technology

- PMLiVE

Successful partnerships in pharma: Skyepharma and Mundipharma

Why skills and flexibility matter more than sheer size

- PMLiVE

Mixed messages for AZ’s benralizumab in COPD study

Respiratory hope misses primary goal in trial data presented at ERS congress

- PMLiVE

GSK trial throws everything at COPD

Tests combination of fluticasone furoate, umeclidinium and vilanterol

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links